ResearcherUniversity of VeronaActive in the last 2 years

Alessandra Fiore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-0141-2862; OpenAlex author ID A5102508195. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 15

Papers, trials and grants by year

2025: 1 paper · 2026: 3 papers

Papers 4

First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models. Co-author DOI 10.1021/acs.jmedchem.6c00235 ↗
Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1111/febs.70223 ↗
Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12943-026-02746-y ↗
Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1 ↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Raffaella Pacchiana · 4 shared papers, 2025–2026 · strength 0.95
Adriana Celesia · 4 shared papers, 2025–2026 · strength 0.95
Massimo Donadelli · 4 shared papers, 2025–2026 · strength 0.95
Federica Danzi · 3 shared papers, 2025–2026 · strength 0.72
Maria Poles · 2 shared papers, 2026 · strength 0.53
- Paper Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal ad… DOI 10.1111/febs.70223 ↗
- Paper Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02746-y ↗
Daniela Cecconi · 2 shared papers, 2025–2026 · strength 0.47
- Paper Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal ad… DOI 10.1111/febs.70223 ↗
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Claudio Luchini · 2 shared papers, 2025–2026 · strength 0.44
- Paper Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-026-02746-y ↗
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Chiara Borsari · 1 shared paper, 2026 · strength 0.23
- Paper First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models. DOI 10.1021/acs.jmedchem.6c00235 ↗
Paola Conti · 1 shared paper, 2026 · strength 0.23
- Paper First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models. DOI 10.1021/acs.jmedchem.6c00235 ↗
Giovanna Butera · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Antonio Pea · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Jessica Brandi · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Costas Andreas Lyssiotis · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Aldo Scarpa · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗
Roberto Salvia · 1 shared paper, 2025 · strength 0.19
- Paper Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. DOI 10.1038/s41419-025-08082-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.